Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans

Blood

Volumn 124, Issue 14, 2014, Pages 2298-2305

  Daneshjou, Roxana ^a   Gamazon, Eric R ^b   Burkley, Ben ^c   Cavallari, Larisa H ^c,d   Johnson, Julie A ^c   Klein, Teri E ^a   Limdi, Nita ^e   Hillenmeyer, Sara ^a   Percha, Bethany ^a   Karczewski, Konrad J ^a   Langaee, Taimour ^c   Patel, Shitalben R ^d   Bustamante, Carlos D ^a   Altman, Russ B ^a   Perera, Minoli A ^b,f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AFRICAN AMERICAN; ALGORITHM; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; EXOME; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE MAP; HOMEOSTASIS; HUMAN; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOGENETICS; POPULATION DYNAMICS; ALLELE; DNA SEQUENCE; GENETICS; GEOGRAPHY; HAPLOTYPE; METABOLISM; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; ALGORITHMS; ALLELES; ANTICOAGULANTS; COHORT STUDIES; EXOME; FOLIC ACID; GEOGRAPHY; HAPLOTYPES; HOMEOSTASIS; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI; SEQUENCE ANALYSIS, DNA; WARFARIN;

EID: 84907683752     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-568436     Document Type: Article

References (49)

1. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2011; April 2012. Report by the IMS Institute for Healthcare Informatics. Available at: www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/ IHII-Medicines-in-U.S-Report-2011.pdf.
2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011; 365(21):2002-2012.
3. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011;9(Suppl 1):12-19.
4. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: metaanalysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397-402.
5. Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.
6. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the doseanticoagulant effect of warfarin. Blood. 2005; 105(2):645-649.
7. Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006;79(4): 291-302.
8. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012;125(16):1997-2005.
9. Kimmel SE, French B, Kasner SE, et al; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369(24):2283-2293.
10. Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing-recalibrating expectations. N Engl J Med. 2013; 369(24):2273-2275.
11. Pirmohamed M, Burnside G, Eriksson N, et al; EU-PACT Group. A randomized trial of genotypeguided dosing of warfarin. N Engl J Med. 2013; 369(24):2294-2303.
12. Schelleman H, Chen Z, Kealey C, et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther. 2007;81(5):742-747.
13. Kealey C, Chen Z, Christie J, et al. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics. 2007;8(3):217-225.
14. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics. 2008;9(5): 511-526.
15. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382(9894):790-796.
16. Liu Y, Jeong H, Takahashi H, et al. Decreased warfarin clearance associated with the CYP2C9 R150H (8) polymorphism. Clin Pharmacol Ther. 2012;91(4):660-665.
17. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87(4):445-451.
18. Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9 8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009;10(8):1243-1255.
19. Ramirez AH, Shi Y, Schildcrout JS, et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics. 2012;13(4):407-418.
20. Emond MJ, Louie T, Emerson J, et al; National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project; Lung GO. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 2012;44(8):886-889.
21. Clark MJ, Chen R, Lam HYK, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011;29(10): 908-914.
22. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8): 904-909.
23. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575.
24. Morris AP, Zeggini E. An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol. 2010;34(2): 188-193.
25. Dimeski G, Badrick T, Flatman R, Ormiston B. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem. 2004;50(12):2391-2392.
26. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics. 2003;164(4):1567-1587.
27. Robbins C, Torres JB, Hooker S, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res. 2007;17(12): 1717-1722.
28. Dunham I, Kundaje A, Aldred SF, et al; ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57-74.
29. NIH Roadmap Epigenomics Mapping Consortium. Roadmap epigenomics project. Available at: http://www.roadmapepigenomics.org. Accessed March 2, 2014.
30. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010;28(8): 817-825.
31. Stranger BE, Montgomery SB, Dimas AS, et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet. 2012;8(4): e1002639.
32. Altshuler DM, Gibbs RA, Peltonen L, et al; International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. Nature. 2010;467(7311): 52-58.
33. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PIW. SNAP: a webbased tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008; 24(24):2938-2939.
34. Pickrell JK, Coop G, Novembre J, et al. Signals of recent positive selection in a worldwide sample of human populations. Genome Res. 2009;19(5): 826-837.
35. Coop G, Pickrell JK, Novembre J, et al. The role of geography in human adaptation. PLoS Genet. 2009;5(6):e1000500.
36. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011;12(7):953-963.
37. Consortium TG; GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-585.
38. Perera MA, Cavallari LH, Johnson JA. Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clin Pharmacol Ther. 2014;95(3):242-244.
39. Daneshjou R, Klein TE, Altman RB. Genotypeguided dosing of vitamin K antagonists. N Engl J Med. 2014;370(18):1762-1763.
40. Fahmi S, Yang C, Esmail S, Hobbs HH, Cohen JC. Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum Mol Genet. 2008;17(14):2101-2107.
41. Lange LA, Hu Y, Zhang H, et al; NHLBI Grand Opportunity Exome Sequencing Project. Wholeexome sequencing identifies rare and lowfrequency coding variants associated with LDL cholesterol. Am J Hum Genet. 2014;94(2): 233-245.
42. Johnson JA, Gong L, Whirl-Carrillo M, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011;90(4): 625-629.
43. Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol. 2003;65(7):1163-1170.
44. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest. 2005;115(1):110-117.
45. Clarke L, Waxman DJ. Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists. Arch Biochem Biophys. 1987; 256(2):585-596.
46. Kim M-S, Pinto SM, Getnet D, et al. A draft map of the human proteome. Nature. 2014;509(7502): 575-581.
47. Muszkat M, Bialer O, Blotnick S, et al. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of longterm administration in adults. Clin Ther. 2010; 32(2):347-356.
48. Mayer O Jr, Simon J, Rosolová H, Hromádka M, Subrt I, Vobrubová I. The effects of folate supplementation on some coagulation parameters and oxidative status surrogates. Eur J Clin Pharmacol. 2002;58(1):1-5.
49. Deol PS, Barnes TA, Dampier K, John Pasi K, Oppenheimer C, Pavord SR. The effects of folic acid supplements on coagulation status in pregnancy. Br J Haematol. 2004;127(2):204-208.